ANNOUNCED AS TEMPORARYNo
On 22 March 2021, the Executive Committee of the Brazilian Foreign Trade Chamber (Gecex) issued Resolution No. 175 eliminating the import tariffs on Risanquizumab, Ranibizumab, as well as Escherichia Coli bacterial lysate capsules. The affected products were classified under the tariff subheadings NCM 3002.15.90 and 3002.90.92.
According to the regulation, prior to this announcement, the affected goods enjoyed an import duty of 2% in the case of Risanquizumab and Ranibizumab, and of 4% in the case of Escherichia Coli bacterial lysate capsules.
Resolution No. 175 is to enter into force on 1 April 2021.
⚑ Please report this page in case you detect an inaccuracy in its content.